Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
Abstract Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, w...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-023-00424-z |
| _version_ | 1797789914844102656 |
|---|---|
| author | Xubo Gong Yi Zhang Xin He Milad Moloudizargari Teng Yu Lin Wang Weiwei Liu Lan Jin Huiying Xu Yang Xu Zhihua Tao Wenbin Qian |
| author_facet | Xubo Gong Yi Zhang Xin He Milad Moloudizargari Teng Yu Lin Wang Weiwei Liu Lan Jin Huiying Xu Yang Xu Zhihua Tao Wenbin Qian |
| author_sort | Xubo Gong |
| collection | DOAJ |
| description | Abstract Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment. |
| first_indexed | 2024-03-13T01:57:24Z |
| format | Article |
| id | doaj.art-68631ef78b8447bda55113a130c5156b |
| institution | Directory Open Access Journal |
| issn | 2162-3619 |
| language | English |
| last_indexed | 2024-03-13T01:57:24Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj.art-68631ef78b8447bda55113a130c5156b2023-07-02T11:09:42ZengBMCExperimental Hematology & Oncology2162-36192023-06-011211410.1186/s40164-023-00424-zVenetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meetingXubo Gong0Yi Zhang1Xin He2Milad Moloudizargari3Teng Yu4Lin Wang5Weiwei Liu6Lan Jin7Huiying Xu8Yang Xu9Zhihua Tao10Wenbin Qian11Department of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The First Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical CenterDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical CenterDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Clinical Laboratory, The Second Affiliated Hospital, Zhejiang University School of MedicineDepartment of Hematology, The Second Affiliated Hospital, Zhejiang University School of MedicineAbstract Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment.https://doi.org/10.1186/s40164-023-00424-zVenetoclaxAcute myeloid leukemiaHypomethylating agents |
| spellingShingle | Xubo Gong Yi Zhang Xin He Milad Moloudizargari Teng Yu Lin Wang Weiwei Liu Lan Jin Huiying Xu Yang Xu Zhihua Tao Wenbin Qian Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting Experimental Hematology & Oncology Venetoclax Acute myeloid leukemia Hypomethylating agents |
| title | Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting |
| title_full | Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting |
| title_fullStr | Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting |
| title_full_unstemmed | Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting |
| title_short | Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting |
| title_sort | venetoclax based therapy for relapsed or refractory acute myeloid leukemia latest updates from the 2022 ash annual meeting |
| topic | Venetoclax Acute myeloid leukemia Hypomethylating agents |
| url | https://doi.org/10.1186/s40164-023-00424-z |
| work_keys_str_mv | AT xubogong venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT yizhang venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT xinhe venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT miladmoloudizargari venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT tengyu venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT linwang venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT weiweiliu venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT lanjin venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT huiyingxu venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT yangxu venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT zhihuatao venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting AT wenbinqian venetoclaxbasedtherapyforrelapsedorrefractoryacutemyeloidleukemialatestupdatesfromthe2022ashannualmeeting |